Crinetics Pharmaceuticals (NASDAQ:CRNX) announced its quarterly earnings results on Tuesday. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.05), Bloomberg Earnings reports. Crinetics Pharmaceuticals had a negative return on equity of 26.96% and a negative net margin of 1,303.31%.
Shares of CRNX stock opened at $18.39 on Wednesday. The business has a fifty day simple moving average of $22.57. Crinetics Pharmaceuticals has a 52 week low of $17.32 and a 52 week high of $42.00. The stock has a market capitalization of $443.90 million and a price-to-earnings ratio of -8.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.04 and a quick ratio of 18.04.
In related news, insider Ventures Iv L.P. 5Am sold 250,000 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $22.20, for a total value of $5,550,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.40% of the company’s stock.
Crinetics Pharmaceuticals Company Profile
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.